TOVX Theriva Biologics, Inc.
NYSE · SEC CIK 894158 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 28 since 2021-12-27, latest 2026-01-06
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| No open-market trades in the last year. | |||
Transactions 7
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-08 | 2023-06-07 | TOVX | SHALLCROSS STEVEN A | CEO, CFO, Dir | P - Purchase | $0.69 | +14.0K | 250.0K | +6% | +$9,660 | |
| 2023-06-07 | 2023-06-06 | TOVX | SHALLCROSS STEVEN A | CEO, CFO, Dir | P - Purchase | $0.63 | +26.0K | 236.0K | +12% | +$16.4K | |
| 2023-02-13 | 2023-02-10 | TOVX | SHALLCROSS STEVEN A | CEO, CFO, Dir | P - Purchase | $1.04 | +25.0K | 210.0K | +14% | +$26.0K | |
| 2023-02-03 | 2023-02-02 | TOVX | SHALLCROSS STEVEN A | CEO, CFO, Dir | P - Purchase | $0.94 | +25.0K | 185.0K | +16% | +$23.5K | |
| 2023-01-26 | 2023-01-25 | TOVX | SHALLCROSS STEVEN A | CEO, CFO, Dir | P - Purchase | $0.87 | +25.0K | 160.0K | +19% | +$21.8K | |
| 2023-01-23 | 2023-01-20 | TOVX | SHALLCROSS STEVEN A | CEO, CFO, Dir | P - Purchase | $0.75 | +25.0K | 135.0K | +23% | +$18.8K | |
| 2023-01-03 | 2022-12-29 | TOVX | SHALLCROSS STEVEN A | CEO, CFO, Dir | P - Purchase | $0.44 | +100.0K | 110.0K | +1,000% | +$44.0K |
Purchase Sale Sale after option exercise All abbreviations